Wells Fargo lowers Amphastar Pharmaceuticals [AMPH] rating to Equal-Weight and sets price target at $21
Wells Fargo took its Amphastar Pharmaceuticals [AMPH] rating to the equivalent of Equal-Weight from Overweight, and the price target to $21.0, in a research note dated 2021-01-08. That figure represents around a 1.69% premium from where the company’s shares closed on Thursday. Other analysts also revised their coverage, with Northland Capital’s analysts upgrading the shares […]